Details
 

September 16, 2020
12:00PM - 1:00PM

MSHO Corporate Sponsor Zoom Meetings

Clovis, GSK, Guardant Health, Kite, Rigel, Taiho

Zoom Meeting

Do you miss having your favorite pharma reps visit your office? MSHO will be hosting a series of Zoom lunch meetings with some of our corporate sponsors. Join your colleagues and pharma friends for 25 minutes of education and seeing each others' smiling faces!

Registration has now closed.  

12:00 pm - 12:25 pm Meetings:

• Kite
  
  • Overview: JUST APPROVED! Groundbreaking therapy for r/r Mantle Cell Lymphoma. As early as second-line.
• Rigel
  
  • Overview: Rigel Update
• Taiho
  
  • Overview: New product Inqovi, and updated information for Lonsurf for mCRC and mGastric Cancer Patients. 

12:35 pm - 1:00 pm Meetings:

• Clovis
  
  • Overview: New Indication!  Rubraca has a new indication in mCRPC! Also, Rubraca for use in recurrent ovarian cancer.
• GSK
  
  • Overview: First in class, off the shelf, BCMA directed monoclonal antibody drug conjugate indicated for RRMM patients previously treated with Proteasome inhibitor, Immunomodulatory agent and an anti-CD38 monoclonal antibody. ZEJULA Now approved for 1L maintenance.  First and only once-daily oral PARP inhibitor for platinum-responsive advanced ovarian cancer.  Proven efficacy in 1L maintenance regardless of biomarker status.
• Guardant Health
  
  • Overview: Exciting new updates for Guardant Health

For questions regarding this event, please contact MSHO at 248-385-5464 or email kblazevski@msho.org.

Printer-Friendly Version